- Conditions
- Acute Coronary Syndrome
- Interventions
- Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 107
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Fludeoxyglucose F-18, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon alfa-2a, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 9
- States / cities
- Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Back Pain, Chronic Low Back Pain, Internal Disc Disruption, Degenerative Disc Disease
- Interventions
- BIOSTAT BIOLOGX, Saline
- Biological · Drug
- Lead sponsor
- Spinal Restoration, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 17 more
- Conditions
- Healthy
- Interventions
- Liothyronine, Levothyroxine, Placebos
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Interventions
- e-Device
- Drug
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 22
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Nivolumab, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
- Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
- Interventions
- Cytokine-Induced Memory-like Natural Killer Cells, Interleukin-2, Venetoclax
- Biological · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Care
- Interventions
- Relational Agent ( RA) Alex
- Behavioral
- Lead sponsor
- Anita Y. Kinney, PhD, RN
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Colorectal Cancer
- Interventions
- Petosemtamab, Cetuximab, Bevacizumab, 5-FU, Leucovorin (Calcium Folinate), Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 3 more
- Conditions
- Bladder Cancer
- Interventions
- eflornithine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 49 more
- Conditions
- HIV Infections
- Interventions
- CD4 Antigens
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Cancer
- Interventions
- Citrulline, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
- Interventions
- Brentuximab Vedotin, Rituximab, Bendamustine
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 22
- States / cities
- Duarte, California • Santa Barbara, California • Torrance, California + 18 more
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
- Interventions
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 28 Days and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- Acthar
- Drug
- Lead sponsor
- Phoenix Neurological Associates, LTD
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • San Diego, California • Columbia, Missouri + 2 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
- Interventions
- DS-1594b, Azacitidine, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin, Mesna, Methotrexate, Prednisone, Rituximab, Venetoclax, Vincristine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Facial Contouring
- Interventions
- OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System, SkinMedica Products, KYBELLA
- Drug · Device · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 10
- States / cities
- Redondo Beach, California • Vista, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more
- Conditions
- Prostate Cancer
- Interventions
- 18F-DCFPyL
- Drug
- Lead sponsor
- Ashok Muthukrishnan
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Necitumumab, Osimertinib, Quality-of-Life Assessment, Questionnaire Administration, Trastuzumab
- Biological · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Keratosis, Actinic
- Interventions
- Aminolevulinic Acid PDT (ALA), Vehicle PDT (VEH)
- Drug
- Lead sponsor
- DUSA Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- San Diego, California • Orange Park, Florida • Austin, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Etanercept, Infliximab, Adalimumab, Placebo
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio